Biocon is trading higher by 5% at Rs 313 after reporting a better-than-expected consolidated net profit at Rs 94 crore for the quarter ended June 30, 2013 (Q1) mainly on account of strong performance in the biopharma segment.
Analyst on an average had expected profit of Rs 82 from the biotechnology firm. The company had posted a net profit of Rs 79 crore in the same quarter last fiscal.
Consolidated total income of the company increased by 21% to Rs 701 crore in Q1 FY2014 quarter as against Rs 577 crore for the year ago period. EBITDA margins improved to 21.69% from 21.28% over the corresponding quarter of previous fiscal, Biocon said in a statement.
The stock opened at Rs 310 and hit a high of Rs 316, nears to its 52-week high of Rs 322 touched on November 16, last year. A combined 739,478 shares changed hands on the counter till 1046 hours on NSE and BSE.
Analyst on an average had expected profit of Rs 82 from the biotechnology firm. The company had posted a net profit of Rs 79 crore in the same quarter last fiscal.
Consolidated total income of the company increased by 21% to Rs 701 crore in Q1 FY2014 quarter as against Rs 577 crore for the year ago period. EBITDA margins improved to 21.69% from 21.28% over the corresponding quarter of previous fiscal, Biocon said in a statement.
The stock opened at Rs 310 and hit a high of Rs 316, nears to its 52-week high of Rs 322 touched on November 16, last year. A combined 739,478 shares changed hands on the counter till 1046 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%